Spots Global Cancer Trial Database for jcar017
Every month we try and update this database with for jcar017 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas | NCT03575351 | Lymphoma, Non-H... | Standard of Car... JCAR017 | 18 Years - 75 Years | Celgene | |
| A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | NCT03310619 | Lymphoma, Non-H... Lymphoma, Large... Lymphoma, Folli... | JCAR017 Durvalumab CC-122 Ibrutinib CC-220 Relatlimab Nivolumab CC-99282 | 18 Years - | Celgene | |
| Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | NCT03436771 | Non Hodgkin Lym... Multiple Myelom... Chronic Lymphoc... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... | JCAR017 JCARH125 | - | Juno Therapeutics, a Subsidiary of Celgene | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | NCT03744676 | Lymphoma, Non-H... Lymphoma Lymphoma, B-Cel... Lymphoma, Large... Neoplasms Neoplasms by Hi... Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... | lisocabtagene m... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | NCT03436771 | Non Hodgkin Lym... Multiple Myelom... Chronic Lymphoc... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... | JCAR017 JCARH125 | - | Juno Therapeutics, a Subsidiary of Celgene | |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) | NCT04245839 | Lymphoma, Non-H... | Fludarabine Cyclophosphamid... JCAR017 | 18 Years - | Celgene | |
| A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) | NCT04245839 | Lymphoma, Non-H... | Fludarabine Cyclophosphamid... JCAR017 | 18 Years - | Celgene | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
